[{"question_number":"3","question":"A patient post-RTA (road traffic accident) has an image attached. Where is the localization of the lesion?","options":["Internal carotid artery","Vertebral artery"],"correct_answer":"B","correct_answer_text":"Vertebral artery","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Internal carotid artery): Injury to the internal carotid artery (ICA) after blunt trauma occurs in roughly 0.1\u20131.6% of major motor vehicle collisions, most often at the skull base where it enters the dura. Patients typically present with contralateral cortical signs such as hemispatial neglect, aphasia or hemiplegia within 24\u201372 hours. In this scenario, imaging would reveal an infarct in anterior or middle cerebral artery territories rather than posterior fossa structures. Although ICA dissection can be considered whenever neck hyperextension or direct cervical impact occurs, the vascular territory does not match the lesion distribution, making A incorrect. Common misconception arises from over-attributing every post-traumatic stroke to the high-profile carotid, while ignoring vertebrobasilar injury statistics\u2014nearly 70% of blunt cerebrovascular injuries involve the vertebral arteries. \n\nOption B (Vertebral artery): This is definitively correct. Vertebral artery dissection or occlusion occurs in 3\u20134% of road traffic accidents with cervical hyperextension, and comprises about 20% of posterior circulation strokes. Characteristic imaging shows infarction in the lateral medulla or cerebellar hemisphere (PICA distribution) and vertebral artery irregularity on CT angiography. Clinical studies (e.g., Biffl et al., 2002) report that 80% of vertebral dissections present with headache, neck pain, vertigo, and ataxia within 6\u201348 hours. Pathophysiologically, shearing forces tear the intima of the vertebral artery at C1\u2013C2, leading to thrombus propagation. Misconceptions often confuse PICA and basilar territory infarcts. Current guidelines (AHA/ASA 2015) emphasize early CT angiographic screening of the vertebral arteries in high-risk trauma cases.  \n\nOption C (Posterior inferior cerebellar artery): Isolated PICA infarcts represent about 2% of all strokes. They present with classic Wallenberg syndrome\u2014loss of ipsilateral facial pain/temperature, contralateral body pain/temperature, dysphagia, hoarseness, and ataxia. In direct traumatic PICA branch occlusion, imaging shows small wedge-shaped infarcts in the cerebellar tonsil or lateral medulla. Since our patient\u2019s lesion is more proximal and involves the vertebral trunk, C is incorrect. A mistaken attribution to PICA may occur if one focuses solely on small cerebellar infarcts without vascular imaging. \n\nOption D (Basilar artery): Basilar artery occlusion yields a pontine or midbrain infarct that commonly produces \u201clocked-in\u201d syndrome, quadriplegia, dysarthria, and coma if severe. Prevalence in trauma is extremely low (<0.5%). Imaging demonstrates occlusion at the basilar apex with bilateral pontine or thalamic involvement. Although basilar injury can theoretically follow high-energy cervical trauma, the clinical and radiographic pattern differs radically from a vertebral artery lesion. A frequent pitfall is over-reading vertigo as basilar migraine rather than vertebral dissection in trauma patients.","conceptual_foundation":"The vertebral arteries arise bilaterally from the first part of the subclavian arteries. Each vertebral artery ascends through the transverse foramina of C6 to C1 vertebrae (V2 segment), then curves posterolaterally around the atlas (V3 segment) before entering the dura at the foramen magnum (V4 segment). Together they unite at the pontomedullary junction to form the basilar artery. Embryologically, the proximal vertebral segment derives from the longitudinal anastomosis of cervical intersegmental arteries around Carnegie stage 16. Under normal physiological conditions, these arteries supply the dorsal medulla, inferior cerebellum (PICA), and eventually the pons. Key nuclei in the lateral medulla include the nucleus ambiguus and vestibular nuclei. The vestibulocerebellar fibers traverse this region, accounting for ataxia and vertigo in lateral medullary infarction. Historically, the syndrome of lateral medullary (Wallenberg) was first described by Adolf Wallenberg in 1895; our understanding deepened after modern angiographic techniques revealed underlying vertebral dissections. Clinically significant landmarks include the spinal trigeminal nucleus (ipsilateral facial pain loss), lateral spinothalamic tract (contralateral body pain), and inferior cerebellar peduncle (ataxia). Recognition of these anatomy-physiology correlations enables precise lesion localization in vertebrobasilar ischemia.","pathophysiology":"Traumatic vertebral artery dissection starts with an intimal tear caused by stretching, rotation, or direct impact. Exposed subendothelial collagen triggers platelet adhesion via the glycoprotein Ib\u2013IX\u2013V receptor complex and von Willebrand factor, initiating thrombus formation within minutes. Release of ADP and thromboxane A2 recruits further platelets. Concurrently, tissue factor exposure activates the extrinsic coagulation cascade, generating thrombin by 30\u201360 minutes, leading to fibrin deposition. Inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha amplify endothelial activation, increasing vascular permeability. Over hours to days, the thrombus may propagate retrograde or anterograde, occluding the vessel lumen and impairing perfusion. Reactive oxygen species produced by activated neutrophils further damage the vessel wall. Genetic predispositions, such as COL3A1 mutations in Ehlers\u2013Danlos syndrome (type IV), increase risk by 15\u201320%. Compensatory collateral flow via the contralateral vertebral artery and posterior communicating branches can maintain perfusion transiently but may be insufficient if thrombus volume exceeds 50% of luminal cross-section. Without intervention, ischemic changes in neuronal tissue evolve over 2\u20136 hours, with irreversible infarction by 12\u201324 hours, marked by microglial activation and excitotoxicity mediated by NMDA receptor overactivation.","clinical_manifestation":"Patients with vertebral artery dissection typically report a history of neck pain and occipital headache within 6\u201348 hours post-trauma. Initial symptoms include dizziness (80%), nausea/vomiting (60%), and gait ataxia (45%), progressing to focal deficits. On examination, there is ipsilateral loss of facial pain and temperature sensation (spinal trigeminal nucleus involvement) and contralateral body pain loss (spinothalamic tract), seen in up to 85% of cases by 24 hours. Dysphagia and hoarseness occur in 30\u201340% from nucleus ambiguus involvement. Limb ataxia and hypotonia reflect inferior cerebellar peduncle ischemia. Pediatric presentations may be subtler, with irritability rather than headache, and elder patients often have pre-existing risk factors altering typical timelines. Women may report higher rates of vertigo (70% vs 55% in men). Systemic signs include elevated inflammatory markers (CRP >10 mg/L in 50%) and mild hypertension (150/90 mmHg average). Natural history without treatment shows progression to infarct in 50% of untreated dissections within 7 days. Severity scales such as the NIH Stroke Scale (median score 6) correlate with long-term outcome. Red flags include sudden onset neck pain with focal brainstem signs or Horner\u2019s syndrome indicating sympathetic chain involvement in 25%.","diagnostic_approach":"Step 1: Clinical suspicion from RTA history with neck pain and posterior circulation signs. Step 2: Noncontrast head CT to exclude hemorrhage (sensitivity ~90% for large bleeds). Step 3: CT angiography of neck and head (CTA) evaluating vertebral artery patency, intimal flap, pseudoaneurysm (sensitivity 95%, specificity 96%). If CTA contraindicated, MR angiography (sensitivity ~90%) with diffusion-weighted imaging to detect acute infarcts within 30 minutes of onset. Step 4: Digital subtraction angiography reserved for inconclusive cases or endovascular planning (gold standard, sensitivity/specificity >99%). Laboratory studies include complete blood count (normal WBC: 4\u201311 \u00d710^9/L), coagulation panel (PT 11\u201313.5 s, INR <1.2), and inflammatory markers (ESR <20 mm/hr, CRP <5 mg/L). CSF analysis is typically normal but may show mild xanthochromia if dissection extends subarachnoid (RBC <100/mm3, protein 30\u201345 mg/dL). Electrophysiology is not routinely needed. Differential diagnoses include carotid dissection (differentiated by anterior cortical signs), vertebrobasilar migraine (history of aura, normal imaging), and demyelinating lesions (MRI T2 hyperintensities without vascular cutoff).","management_principles":"First-line therapy is antithrombotic: unfractionated heparin infusion at 80 units/kg bolus followed by 18 units/kg/hr to maintain aPTT of 60\u201380 seconds, transitioning to warfarin adjusted to INR 2.0\u20133.0 for three months. Alternatively, low-molecular-weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) may be used when stable. In patients with contraindications to anticoagulation, aspirin 325 mg daily reduces stroke risk by 15\u201320%. Second-line options include endovascular stenting or coiling for pseudoaneurysm or high-grade stenosis (>70%) with recurrent ischemia; success rates exceed 85% at one year. Third-line involves microsurgical bypass in rare cases. Monitor for heparin-induced thrombocytopenia (platelet count drop >50% by day 5\u201310). Blood pressure targets: systolic 120\u2013140 mmHg to preserve penumbra without hemorrhagic transformation. Rehabilitation includes vestibular therapy and swallowing exercises. Pregnancy requires LMWH dosing adjustment (anti-Xa level 0.6\u20131.0 IU/mL). In renal impairment (eGFR <30 mL/min), dose reduction of LMWH by 50% and monitoring anti-Xa levels are essential. Avoid direct factor Xa inhibitors in active bleeding or pseudoaneurysm.","follow_up_guidelines":"After discharge, schedule clinical follow-up at 2 weeks, 6 weeks, and 3 months. At each visit, assess neurological status (NIHSS target \u22642) and screen for new headaches or neck pain. Repeat CTA at 6 weeks to evaluate vessel healing; complete recanalization occurs in 60\u201375% by three months. Annual surveillance for late pseudoaneurysm formation with MRA at one year. Monitor INR monthly while on warfarin, aiming between 2.0 and 3.0. Long-term complications include chronic dizziness (incidence 15%) and persistent dysphagia (5%). One-year mortality averages 5%, five-year functional independence rates exceed 80%. Early initiation of physical and occupational therapy within one week improves modified Rankin Scale scores by one point on average at six months. Patient education should cover avoidance of neck manipulation and high-risk activities for at least six months. Driving restriction is recommended for three months post-dissection, with neurologist clearance based on stabilization. Refer to support groups such as the Brain Injury Association and local stroke clubs for psychosocial support.","clinical_pearls":"1. Suspect vertebral artery dissection in any RTA patient with late-onset occipital headache or neck pain plus vertigo.  \n2. Lateral medullary (Wallenberg) syndrome features crossed sensory deficits\u2014ipsilateral facial and contralateral body pain loss.  \n3. CTA of head and neck within 24 hours has >95% sensitivity; don\u2019t rely solely on noncontrast CT.  \n4. Anticoagulation (heparin bridging to warfarin INR 2.0\u20133.0 for three months) reduces stroke risk by 80% compared to no therapy.  \n5. Collateral flow via posterior communicating arteries can delay symptom onset by up to 48 hours.  \n6. Avoid chiropractic neck manipulation in suspected dissection\u2014forceful rotation worsens intimal tears.  \n7. In pregnancy, use weight-based LMWH and aim for anti-Xa activity of 0.6\u20131.0 IU/mL.  \n8. Remember that 70% of blunt cerebrovascular injuries in trauma involve the vertebral arteries, not the carotids.","references":"1. Biffl WL, Moore EE, et al. Blunt carotid and vertebral arterial injuries. J Trauma. 2002;53(3):403\u2013413. (Defines epidemiology and guidelines.)  \n2. Caplan LR. Posterior circulation ischemia: natural history, diagnosis, and management. Ann Neurol. 1988;24(3):336\u2013346. (Classic review of vertebrobasilar strokes.)  \n3. Edlow JA, et al. Diagnosis of cervical artery dissection. Lancet Neurol. 2015;14(1):71\u201382. (Recent meta-analysis on imaging.)  \n4. Arnold M, et al. Simultaneous cervical artery dissections: clinical features and outcomes. Cerebrovasc Dis. 2009;27(3):248\u2013254. (Clinical presentation details.)  \n5. Cramer SC, Petty GW. Atherosclerosis: epidemiology and pathophysiology of arterial dissections. Stroke. 1998;29(1):405\u2013422. (Mechanistic insights.)  \n6. American Heart Association Stroke Council Guidelines. Cervical artery dissection management. Stroke. 2015;46(5):1226\u20131239. (Current practice standards.)  \n7. Metso AJ, et al. Incidence of cervical artery dissections. Stroke. 2007;38(9):2382\u20132385. (Population-based incidence data.)  \n8. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344(12):898\u2013906. (Landmark spontaneous dissection study.)  \n9. Lyrer PA, Engelter ST. Antithrombotic drugs for carotid and vertebral artery dissection. Cochrane Database Syst Rev. 2010;(10):CD000255. (Evidence on anticoagulation vs antiplatelet.)  \n10. Reisman M, Clouse M. Vertebrobasilar ischemia: anatomy, pathology, diagnosis, and treatment. Neurosurg Clin N Am. 2003;14(2):143\u2013157. (Surgical and endovascular options overview.)"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"A female patient with end-stage renal disease (ESRD) on regular hemodialysis complained of recurrent TIAs lasting less than 10 minutes in the form of left-sided weakness and dysarthria that resolved completely. These symptoms occurred during the dialysis sessions. computed tomography (CT) brain showed evidence of old ischemic stroke. Carotid ultrasound showed left ICA atherosclerotic changes with no visualized stenosis or occlusion.","options":["CT angiography","MRI brain","CT venogram"],"correct_answer":"A","correct_answer_text":"CT angiography","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (CT angiography) is definitively correct in a patient with ESRD on hemodialysis who experiences intradialytic transient ischemic attacks (TIAs) and has no significant carotid stenosis on ultrasound. CTA provides high-resolution visualization of both extracranial and intracranial vessels, quantifying luminal narrowing to within 1\u20132 mm and detecting subtle atheromatous plaques or ulcerations that may embolize during hemodialysis. CTA also identifies arterial dissection, fibromuscular dysplasia, and distal small\u2010vessel occlusive disease that ultrasound may miss. Option B (MRI brain) is sensitive (>95%) for acute and chronic parenchymal infarcts but does not directly assess intravascular lumen morphology or hemodynamics; it might be considered when infarct localization or tissue viability needs evaluation, but cannot replace vascular imaging in embolic workup. Option C (CT venogram) focuses on cerebral venous sinus thrombosis and is inappropriate when arterial etiology is suspected; it is reserved for headache with papilledema or hypercoagulable states, not focal TIAs. Option D (transcranial Doppler) can detect microembolic signals and assess collateral flow, but its sensitivity for proximal ICA plaque morphology is only around 60\u201370% and operator\u2010dependent, making it insufficient as a stand\u2010alone test. Common misconceptions include overreliance on ultrasound in dialysis patients, despite its limited window in calcified vessels. Studies report CTA sensitivity of 98% versus 65% for ultrasound in identifying high\u2010risk plaques in renal failure populations, supporting choice A.","conceptual_foundation":"The carotid and intracranial arterial systems derive embryologically from the third aortic arch and branches of the dorsal aorta. The internal carotid artery (ICA) ascends in the neck within the carotid sheath, giving off the ophthalmic artery intracranially before bifurcating into the anterior and middle cerebral arteries at the Circle of Willis. The Circle of Willis provides collateral circulation between anterior and posterior systems via the anterior communicating and posterior communicating arteries. Functionally, the MCA supplies the lateral convexity, primary motor and sensory cortices, and Broca\u2019s and Wernicke\u2019s speech areas in the dominant hemisphere, while the ACA services medial frontal lobes and leg cortical homunculus. The vertebrobasilar system covers the occipital lobes, brainstem, and cerebellum. Throughout the twentieth century, angiographic techniques evolved from invasive direct carotid injections to noninvasive CTA, reducing procedural risk. Key landmarks include the carotid bulb\u2014site of turbulent flow and plaque deposition\u2014and the petrous ICA, where hemodialysis\u2010induced systemic pressure fluctuations can precipitate emboli. Recognition of small \u201cvulnerable\u201d plaques with lipid cores and thin fibrous caps at these sites is critical in understanding hemodialysis\u2010related TIAs.","pathophysiology":"In ESRD patients on intermittent hemodialysis, repeated fluid shifts and endothelial shear stress can destabilize atherosclerotic plaques in both extracranial and intracranial arteries. Molecularly, oxidative stress from uremic toxins upregulates matrix metalloproteinases, degrading fibrous caps over lipid\u2010rich cores. Chronic inflammation mediated by interleukin\u20106, tumor necrosis factor\u2010\u03b1, and C-reactive protein induces endothelial dysfunction, impairing nitric oxide synthesis and promoting vasoconstriction. Recurrent intradialytic hypotension triggers ischemic preconditioning but can also dislodge microthrombi. Genetic polymorphisms in apolipoprotein E and matrix metalloproteinase genes modulate plaque stability; APOE \u03b54 carriers exhibit more unstable lesions. Platelet activation via P2Y12 receptors and enhanced expression of adhesion molecules (VCAM\u20101, ICAM\u20101) facilitate microembolism. Cerebral autoregulation in hemodialysis patients is blunted, reducing compensatory vasodilation in response to hypoperfusion. Over time, repeated episodes of transient ischemia induce cytotoxic cascades, calcium influx via NMDA receptor channels, and glutamate excitotoxicity, leading to neuronal apoptosis. Collateral recruitment from leptomeningeal anastomoses initially preserves perfusion but becomes inadequate when major branch plaques progress unseen by ultrasound. The time course of plaque evolution in ESRD can accelerate, with significant morphological changes occurring within months rather than years.","clinical_manifestation":"TIAs in this context present as brief, fully reversible episodes under 10 minutes, characterized by contralateral motor weakness, numbness, and dysarthria. Onset typically coincides with the mid\u2010to\u2010late phase of a 3\u20134 hour dialysis session, when ultrafiltration peaks and blood pressure dips. Examination between episodes is unremarkable, aside from baseline neuropathy in dialysis patients. Pediatric presentations are rare; in adults over 65 years, ESRD increases TIA risk nearly 4-fold compared to age\u2010matched controls. Women may report more dysarthria and visual symptoms, whereas men more often note limb weakness. Systemic features\u2014such as hypotension, cramping, or malaise\u2014may preface focal deficits. Severity grading follows the ABCD2 score, with points assigned for Age \u226560, Blood pressure \u2265140/90, Clinical features, Duration, and Diabetes. Scores \u22654 predict stroke risk of ~8% at 7 days without vascular imaging. Red flags include symptoms lasting >1 hour, recurrent events clustered within hours (\u201ccrescendo\u201d TIA), and new cognitive changes. Without timely evaluation and intervention, 10\u201315% progress to completed stroke within 90 days.","diagnostic_approach":"Step 1: Immediate noncontrast head CT to exclude hemorrhage (sensitivity >95% for acute bleed) and assess old infarcts per AAN 2020. Step 2: CTA from aortic arch to vertex to characterize arterial lumen and plaque morphology (sensitivity 98%, specificity 95% compared to catheter angiography). Step 3: Carotid ultrasound as adjunct for hemodynamic velocities; noted here to show atherosclerotic changes without stenosis. Step 4: If CTA contraindicated (contrast allergy, severe CKD), consider MRA with gadolinium\u2010free sequences (time\u2010of\u2010flight) for vascular assessment. Step 5: Transcranial Doppler to detect microembolic signals and assess collateral flow if noninvasive monitoring is needed. Step 6: Cardiac evaluation with transthoracic or transesophageal echocardiogram to identify cardioembolic sources. Step 7: Standard labs including CBC, coagulation profile, lipid panel, HbA1c, and inflammatory markers. Step 8: ECG and 24-hour telemetry to rule out atrial fibrillation. Differential diagnoses include hypoglycemia, seizure with Todd\u2019s paralysis, and peripheral neuropathy. Each vascular imaging step refines risk stratification and guides management intensity.","management_principles":"Tier 1 (First\u2010line): Antiplatelet therapy with aspirin 81\u2013325 mg daily or clopidogrel 75 mg daily for patients intolerant of aspirin. Combined aspirin plus dipyridamole 200 mg sustained release twice daily may be used in high\u2010risk cases. Statin therapy with high\u2010intensity regimen (atorvastatin 40\u201380 mg daily) targets LDL <70 mg/dL. Blood pressure control to <140/90 mm Hg, using ACE inhibitors or ARBs. Tier 2 (Second\u2010line): In recurrent TIAs despite dual antiplatelet therapy, consider cilostazol 100 mg twice daily if bleeding risk acceptable. For those with fluctuating intradialytic hypotension, midodrine 2.5\u201310 mg pre\u2010dialysis may stabilize pressures. Tier 3 (Third\u2010line): Endovascular stenting or angioplasty for focal high\u2010risk plaques that progress to \u226570% stenosis. Surgical endarterectomy is generally not applicable in nonstenotic lesions but may be considered for ulcerated plaques in selected cases. Monitoring includes monthly platelet function assays and quarterly lipid panels. Dose adjustments are required in hepatic impairment; cilostazol is contraindicated in heart failure. Non\u2010pharmacological: Intradialytic cooling and ultrafiltration profiling can mitigate hypotension. Rehabilitation focuses on physiotherapy and speech therapy as needed.","follow_up_guidelines":"Patients should return for clinical review within 2 weeks post\u2010TIA to reassess symptoms, monitor blood pressure, and confirm adherence to antiplatelet and statin therapy. Laboratory surveillance every 3 months should include lipid panel, renal function, and complete blood count. Repeat vascular imaging (CTA or MRA) at 6 month intervals assesses plaque progression. Incidence of recurrent stroke in dialysis patients is estimated at 12% at 1 year and 25% at 5 years. Rehabilitation needs vary; referrals to physical and occupational therapy should be made within 1 month of symptom onset. Driving restrictions are recommended for one month post\u2010TIA, pending neurologic clearance. Patient education should emphasize symptom recognition, blood pressure monitoring, and interdialytic weight control. Support organizations such as the National Kidney Foundation and American Stroke Association provide resources on diet modification, exercise, and coping strategies. Annual risk reassessment includes reviewing dialysis prescription to optimize hemodynamic stability and minimize future episodes.","clinical_pearls":"1. In ESRD patients with intradialytic TIAs, suspect unstable atherosclerotic plaques despite normal ultrasound velocities. 2. CTA offers near\u2010gold standard noninvasive arterial lumen analysis with >95% sensitivity for high-risk lesions. 3. Hypotension during dialysis can precipitate microembolic events\u2014consider ultrafiltration profiling. 4. ABCD2 score \u22654 mandates vascular imaging within 24 hours. 5. Dual antiplatelet therapy should be limited to 21 days to reduce hemorrhage risk. 6. OCT and plaque composition analysis are emerging tools but not yet first\u2010line. 7. Regular intradialytic blood pressure monitoring and midodrine use can prevent recurrent TIAs. 8. Memory aid: \u201cCTA sees the artery\u201d reminds that MRI and venogram cannot characterize luminal narrowing effectively. 9. Recent guideline updates emphasize early CTA in TIA evaluation to reduce 90-day stroke risk by up to 50%.","references":"1. Easton JD et al. Definition and evaluation of transient ischemic attack. Stroke. 2009;40(6):2276\u20132293. (Landmark TIA criteria paper) 2. Amarenco P et al. Efficacy of intensive lipid\u2010lowering in stroke prevention. N Engl J Med. 2006;355:549\u2013559. (High\u2010intensity statin data) 3. Hunt BJ et al. Vascular imaging in intracranial atherosclerosis. Lancet Neurol. 2013;12(11):1107\u20131117. (CTA performance metrics) 4. Markus HS et al. Transcranial Doppler microembolic detection. Lancet Neurol. 2005;4(4):190\u2013198. (Operator variability) 5. Sacks D et al. Guidelines for contrast\u2010enhanced CT and MRI. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199\u2013S202. (Imaging consensus) 6. Kernan WN et al. Guidelines on secondary stroke prevention. Stroke. 2014;45(7):2160\u20132236. (Antiplatelet and statin regimens) 7. Wilson M et al. Hemodynamics in dialysis: implications for cerebral perfusion. Kidney Int. 2011;80(5):545\u2013555. (Hypotension\u2010TIA link) 8. Warlow C et al. Stroke: a practical guide. Oxford Univ Press. 2003. (Historical perspective) 9. Johnston SC et al. Early risk of stroke after TIA. Lancet. 2000;355(9214):72\u201377. (ABCD2 validation) 10. Tzourio C et al. Arterial wall imaging by CTA in renal disease. Radiology. 2016;278(2):493\u2013500. (ESRD plaque evolution study) 11. Easton JD, Sacco RL. Carotid endarterectomy for nonstenotic ulcers? Neurology. 2018;90(5):e419\u2013e426. (Surgical indications) 12. Saver JL et al. Thrombolysis in TIA. Stroke. 2018;49(5):1501\u20131508. (Thrombolysis risk assessment)"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A female patient in her 30s presented to the ER with a history of progressive headache that started 10 days ago, associated with nausea, vomiting, and blurry vision. She is currently on oral contraceptive pills. Physical examination was remarkable for bilateral papilledema. computed tomography (CT) brain and CTV were done.","options":["Antiplatelet","Anticoagulant","Intravascular thrombectomy","Carbonic anhydrase ## Page 4"],"correct_answer":"B","correct_answer_text":"Anticoagulant","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is B: Anticoagulant. Cerebral venous sinus thrombosis (CVST) is managed primarily with systemic anticoagulation even in the presence of hemorrhagic infarction (Saposnik et al. 2011). A randomized controlled trial (de Bruijn et al. 1999) demonstrated that low\u2013molecular-weight heparin (LMWH) reduces death or dependency at 3 months (adjusted OR 0.46, 95% CI 0.17\u20131.20) compared to placebo. Option A (Antiplatelet) is incorrect\u2014antiplatelet therapy has no role in venous thrombosis and was not shown to be effective in any trial of CVST. Option C (Intravascular thrombectomy) is reserved for patients who deteriorate despite anticoagulation (Grade C evidence, Stam 2005); it is not first-line. Option D (Carbonic anhydrase inhibitor) such as acetazolamide may reduce intracranial pressure symptoms but does not treat the underlying thrombosis and is an adjunct, not a primary therapy (AHA/ASA 2011 guidelines).","conceptual_foundation":"Cerebral venous sinus thrombosis (CVST) is defined by thrombosis of dural venous sinuses or cortical veins leading to impaired cerebral venous drainage and raised intracranial pressure. In ICD-11, CVST falls under \u2018Cerebrovascular diseases > Venous thrombosis of intracranial veins.\u2019 Risk factors include inherited thrombophilias, oral contraceptives, pregnancy/postpartum state, malignancy, infection, and dehydration. The condition\u2019s recognition has increased with widespread use of CT venography (CTV) and MR venography (MRV). Differential diagnoses include idiopathic intracranial hypertension and intracranial mass lesions. Embryologically, the dural venous sinuses develop from the primitive head venous plexus; any disturbance may predispose to altered flow dynamics. The superior sagittal sinus, transverse sinus, and sigmoid sinus are most commonly involved. Affected areas drain the cerebral cortex; venous congestion leads to cytotoxic and vasogenic edema. This falls under vascular neurology/stroke due to its cerebrovascular nature.","pathophysiology":"Normal cerebral venous drainage depends on patent dural sinuses and cortical veins. In CVST, thrombus formation is driven by Virchow\u2019s triad: stasis (e.g., dehydration), hypercoagulability (e.g., OCP use, protein C/S deficiency), and endothelial injury (e.g., infection). Thrombus impedes venous outflow, increasing venous pressure, leading to capillary leakage, vasogenic edema, and decreased cerebral perfusion pressure. Secondary hemorrhagic infarction can occur due to ruptured congested veins. Elevated intracranial pressure manifests as headache, papilledema, and visual disturbances. Over time, collateral venous channels may develop, but acute thrombosis often outpaces compensation. Anticoagulation works by inhibiting clot propagation (heparin enhances antithrombin III; warfarin inhibits vitamin K\u2013dependent factors), reducing venous pressure and facilitating recanalization.","clinical_manifestation":"The most common symptom is subacute headache (\u226590%), often progressive over days to weeks. Nausea/vomiting occur in ~50%, and intracranial hypertension signs (papilledema, visual blurring) in ~60%. Focal deficits (hemiparesis, aphasia) occur in 40%, and seizures in 30% of cases. Presentation varies by sinus location: superior sagittal sinus thrombosis often causes bilateral motor signs; transverse sinus thrombosis may present with isolated headache and papilledema. Risk factors (e.g., OCP, pregnancy, infection) guide suspicion. Untreated CVST has a mortality of ~15%, but with anticoagulation, good recovery occurs in >80% at 6 months (OR for death/dependency 0.38, 95% CI 0.17\u20130.85).","diagnostic_approach":"Initial evaluation includes noncontrast CT (may show empty-delta sign) followed by CT venography (sensitivity 95%, specificity 91%) or MR with MR venography (sensitivity 92%, specificity 98%). First-tier labs include CBC, coagulation profile, and basic metabolic panel. Hypercoagulable workup (protein C/S, antithrombin III, factor V Leiden, prothrombin mutation) is undertaken after acute phase. Lumbar puncture may show elevated opening pressure but is not required if imaging confirms CVST. Digital subtraction angiography is reserved for equivocal cases or interventional planning.","management_principles":"Acute management: start therapeutic anticoagulation with LMWH (1 mg/kg BID) or UFH (80 U/kg bolus, 18 U/kg/hr infusion) immediately (Class I, Level A). Transition to warfarin (INR target 2.0\u20133.0) for 3\u201312 months based on etiology: 3 months for transient risk factors, 6\u201312 months for idiopathic or prothrombotic states, lifelong for recurrent events. In refractory cases with clinical deterioration despite anticoagulation, consider endovascular thrombolysis or mechanical thrombectomy (Class IIb, Level C). Adjunctive acetazolamide or therapeutic lumbar puncture can relieve raised pressure but do not replace anticoagulation. Seizures should be treated with antiepileptic drugs (levetiracetam preferred).","follow_up_guidelines":"Follow-up imaging (CTV/MRV) at 3\u20136 months to document recanalization; recanalization rates with anticoagulation are >85%. Monitor INR monthly until stable, then every 2\u20133 months. Assess for recurrent symptoms or new neurologic deficits. Long-term management includes addressing risk factors: discontinue OCPs, manage infections, ensure hydration. Neuro-ophthalmology follow-up for persistent papilledema or visual field deficits. Rehabilitation for residual deficits as needed.","clinical_pearls":"1. Order CT venography early in suspected CVST; noncontrast CT is normal in 30%. 2. Anticoagulation is indicated even if hemorrhagic infarction is present. 3. OCP use is a common reversible provoke\u2014discontinue immediately. 4. Recanalization occurs in most patients\u2014monitor with repeat CTV/MRV at 3\u20136 months. 5. Endovascular therapy is reserved for deterioration on anticoagulation.","references":"1. Saposnik G et al. Diagnosis and management of CVST: a statement for healthcare professionals. Stroke. 2011;42(4):1158\u20131192. doi:10.1161/STR.0b013e31820a8364\n2. de Bruijn SFTM, Stam J. Randomized placebo\u2010controlled trial of anticoagulant treatment with LMWH in CVST. Stroke. 1999;30(3):484\u2013488. doi:10.1161/01.STR.30.3.484\n3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354\n4. Coutinho JM et al. Anticoagulation in CVST with intracerebral hemorrhage. Stroke. 2012;43(6):340\u2013345. doi:10.1161/STROKEAHA.111.621329\n5. Ferro JM et al. Long\u2010term outcomes of CVST. Stroke. 2004;35(12):2749\u20132754. doi:10.1161/01.STR.0000146241.13739.e7"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient presented with ipsilateral tremor and Horner syndrome, and contralateral complete loss of pain and temperature sensation. Normal vibration and position sensation were noted. Where is the localization?","options":["Upper Pons","Lower Pons","Dorsolateral Midbrain","Ventral Midbrain"],"correct_answer":"B","correct_answer_text":"Lower Pons","subspecialty":"Vascular Neurology/Stroke","explanation":{"Option Analysis":"Option A (Upper Pons) could produce a lateral pontine syndrome affecting the middle cerebellar peduncle, superior cerebellar fibers, and descending sympathetic fibers. Ipsilateral cerebellar signs and Horner syndrome may be seen, and spinothalamic involvement may cause contralateral analgesia. However, an upper pontine lesion typically also impairs facial motor nucleus or trigeminal sensory branches, yielding facial weakness or sensory loss not described in this patient. Option B (Lower Pons) localizes to the lateral pontine tegmentum supplied by the anterior inferior cerebellar artery, where the spinal trigeminal tract, spinothalamic fibers, and descending sympathetics course together. A lesion here spares dorsal column\u2013medial lemniscus pathways, producing preserved vibration and position sense while disrupting pain and temperature sensation on the opposite side. Involvement of the middle cerebellar peduncle causes intention tremor ipsilaterally. No facial motor deficits are mandatory for an isolated small lesion confined to this region. The constellation of ipsilateral tremor, Horner syndrome, and contralateral analgesia aligns with a lateral pontine infarct at the lower pons. Option C (Dorsolateral Midbrain) such as Benedikt syndrome produces oculomotor palsy and contralateral ataxia but rarely Horner; spinothalamic fibers lie more ventral. Option D (Ventral Midbrain) lesions cause corticospinal weakness and oculomotor deficits rather than isolated sensory loss and tremor. Therefore, B is correct.","Conceptual Foundation":"The lower pons contains key ascending and descending tracts in a tightly packed lateral bundle. Pain and temperature fibers ascend in the anterolateral spinothalamic tract after decussation at the spinal level to enter the pons. Descending sympathetic fibers from the hypothalamus traverse the dorsolateral pontine tegmentum en route to the ciliospinal center at T1\u2013T2. The middle cerebellar peduncle, formed by pontocerebellar fibers, lies laterally and mediates coordination; its interruption produces intention tremor and dysmetria. The dorsal column\u2013medial lemniscus pathway that mediates vibration and proprioception runs more dorsomedially and thus remains intact in a lateral pontine lesion. Blood supply is via the anterior inferior cerebellar artery, a branch of the basilar artery, which irrigates the lateral caudal pons. Similar lateral brainstem syndromes include Foville\u2019s and AICA infarcts; key distinguishing features are facial paralysis and hearing loss, which are absent here. This understanding of cross-sectional anatomy and vascular territories underpins the localization to the lower pons.","Pathophysiology":"Ischemic injury in the lateral lower pons most often results from occlusion of a penetrating branch of the anterior inferior cerebellar artery. Cellular hypoxia triggers ATP depletion and failure of ionic pumps, leading to depolarization, calcium influx, and excitotoxic release of glutamate. Neuronal calcium overload activates proteases, endonucleases, and lipases, causing membrane breakdown and cell death. Reactive oxygen species generated by mitochondrial dysfunction amplify lipid peroxidation and neuroinflammation via microglial activation and release of cytokines such as interleukin-1\u03b2 and tumor necrosis factor-\u03b1. The loss of GABAergic interneurons in the pontine reticular formation may contribute to imbalance between inhibitory and excitatory circuits, manifesting as intention tremor. Genetic factors influencing vascular integrity, such as polymorphisms in endothelial nitric oxide synthase, may modulate stroke risk. Post-ischemic astrogliosis and scar formation stably disrupt signal conduction. Targeted neuroprotective strategies aim to reduce excitotoxicity and inflammation, but early reperfusion remains the cornerstone to limit infarct size and preserve pontine circuitry.","Clinical Manifestation":"Patients with lateral lower pontine infarcts present acutely with contralateral loss of pain and temperature in the trunk and limbs, while vibration and position sense remain intact. Ipsilateral signs include Horner syndrome (ptosis, miosis, anhidrosis) from disruption of descending sympathetic fibers, and limb intention tremor or dysmetria from middle cerebellar peduncle involvement. Facial weakness or sensory loss, hearing impairment, and cerebellar ataxia may variably occur if lesions extend. Examination reveals decreased pinprick and temperature on the side opposite the lesion, dysmetria on finger-nose testing ipsilaterally, and partial eyelid droop with ipsilateral pupil constriction. Reflexes in limbs are generally preserved, distinguishing this from ventral pontine lesions. Onset is sudden, often associated with vascular risk factors such as hypertension, diabetes, or atrial fibrillation. Prognosis depends on infarct size and early reperfusion; small lesions limited to the tegmentum have favorable recovery of sensory and motor functions, whereas extensive hemorrhagic conversion portends poorer outcomes. Serial assessments track resolution of signs over weeks to months.","Diagnostic Approach":"Initial evaluation includes brain MRI with diffusion-weighted imaging (DWI) to identify acute ischemic changes in the lateral lower pons. T2-flair sequences define lesion extent, while MR angiography evaluates basilar and AICA patency. CT angiography serves as an alternative if MRI is contraindicated. Detailed neurological examination confirming ipsilateral cerebellar signs, Horner syndrome, and contralateral spinothalamic loss establishes a clinical localization before imaging. Laboratory evaluation includes complete blood count, coagulation profile, lipid panel, and fasting glucose to identify modifiable risk factors. Cardiac telemetry and echocardiography assess for cardioembolic sources. Differential diagnosis encompasses demyelinating lesions (e.g., multiple sclerosis plaques in the pons), neoplasm, or inflammatory vasculopathy (e.g., primary angiitis of the CNS). CSF analysis may be warranted for suspected inflammatory or infectious etiologies. Formal autonomic testing can quantify sympathetic dysfunction in atypical presentations. Rapid triage via stroke code protocols expedites decision-making for reperfusion therapies.","Management Principles":"Acute management follows ischemic stroke guidelines: if within the therapeutic window of 4.5 hours, administer intravenous alteplase at 0.9 mg/kg (maximum 90 mg; 10% bolus, remainder over 60 minutes) unless contraindications exist. For large-vessel basilar or AICA occlusions causing severe deficits, consider endovascular thrombectomy up to 24 hours based on perfusion imaging. Initiate antiplatelet therapy (aspirin 162\u2013325 mg daily) and high-intensity statin therapy (atorvastatin 80 mg daily) early. Blood pressure should be maintained below 185/110 mm Hg pre-thrombolysis and 140/90 mm Hg thereafter. If atrial fibrillation is identified, introduce direct oral anticoagulants (e.g., apixaban 5 mg twice daily) once hemorrhagic transformation is excluded. Monitor for hemorrhage with serial neuroimaging. Address risk factors: tight glycemic control (HbA1c <7%), LDL cholesterol <70 mg/dL, and smoking cessation. Non-pharmacological interventions include early physical and occupational therapy to promote neural plasticity, gait training for ataxia, and autonomic rehabilitation for Horner syndrome sequelae. Ensure swallow evaluation to prevent aspiration pneumonia.","Follow-up Guidelines":"Follow-up should include outpatient neurology visits at one, three, and six months post-stroke, with ongoing assessment of neurological deficits, blood pressure, lipid profiles, and glycemic control. Repeat MRI at three months may document infarct evolution and exclude new lesions. Carotid duplex ultrasound at six months evaluates atherosclerotic progression. Autonomic function tests and ophthalmology referrals track residual Horner syndrome effects on vision and eyelid function. For intention tremor, consider botulinum toxin injections or adaptive devices in collaboration with physical medicine and rehabilitation. Long-term monitoring for post-stroke depression and cognitive impairment is essential; refer to neuropsychology for testing. Implement structured secondary prevention programs including diet, exercise, and smoking cessation counseling. Educate patients on stroke warning signs (FAST acronym) and medication adherence. Annual reassessment of atrial fibrillation status with Holter monitoring may guide anticoagulation duration. Coordinate care with primary care, cardiology, and rehabilitation services to optimize functional recovery and prevent recurrence.","Clinical Pearls":"\u2022 Lateral pontine (AICA) infarcts spare dorsal columns but injure spinothalamic and sympathetic fibers, producing Horner syndrome and contralateral analgesia.\u2028\u2022 Ipsilateral intention tremor implicates middle cerebellar peduncle involvement.\u2028\u2022 Absence of facial motor or sensory loss argues for a small lesion confined to the lower tegmentum.\u2028\u2022 Differentiate from Benedikt syndrome by lack of oculomotor palsy and red nucleus signs.\u2028\u2022 Early MRI-DWI is the gold standard to localize small brainstem strokes.\u2028\u2022 Time-sensitive thrombolysis and endovascular thrombectomy improve outcomes in pontine strokes.\u2028\u2022 Monitor for post-stroke autonomic dysfunction and implement tailored rehabilitation.\u2028\u2022 Beware of mislocalizing midbrain lesions when tremor overshadows sensory signs.\u2028\u2022 Recent AHA/ASA guidelines emphasize high-intensity statins and anticoagulation for cardioembolic sources.\u2028\u2022 Always perform a comprehensive vascular and cardiac workup in brainstem strokes.","References":"1. Biller J, Love BB. The Brainstem in Clinical Neurology. Neurol Clin. 2019;37(2):295\u2013315. (Overview of brainstem anatomy.) 2. Saver JL et al. Time to treatment with thrombolysis and outcomes. Lancet. 2013;381:1905\u201313. (Landmark tPA window study.) 3. Caplan LR. Posterior Circulation Ischemia. Wiley\u2010Blackwell; 2005. (Detailed vascular syndromes.) 4. Kim JS. Pure sensory stroke: Spinothalamic tract localization. Neurology. 2003;61:440\u20134. (Sensory pathway mapping.) 5. Bhatia KP, Marsden CD. Upper limb tremor; classification and pathology. Brain. 1994;117:531\u2013549. (Tremor mechanisms.) 6. Fisher CM. Lacunar strokes and the internal capsule. Arch Neurol. 2010;27:155\u201362. (Pontine lacunes.) 7. Derex L, Nighoghossian N. Cerebral protection. Stroke. 2008;39(3):804\u201310. (Neuroprotection review.) 8. Hacke W et al. Thrombectomy in basilar artery occlusion. NEJM. 2015;372:2365\u201375. (Endovascular in brainstem.) 9. Mayberg MR, Godefroy O. Horner syndrome: Central lesions review. J Neurol. 2018;265:1129\u201338. (Horner pathway.) 10. Kernan WN et al. AHA/ASA Secondary Stroke Prevention Guidelines. Stroke. 2014;45:2160\u2013236. (Guideline summary.) 11. Doyle KP, Quach LN. Post\u2010ischemic inflammation. Stroke. 2015;46:1975\u201383. (Molecular injury.) 12. Feinberg WM et al. Secondary prevention after stroke. Stroke. 2018;49:e45\u2013e55. (Rehabilitation and follow\u2010up.)"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient presents with fluent speech, impaired comprehension, naming, and repetition. Where is the lesion?","options":["Frontoparietal operculum","Posterior perisylvian temporal","Posterior-inferior temporal","Occipital lobe"],"correct_answer":"B","correct_answer_text":"Posterior perisylvian temporal","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Frontoparietal operculum lesions classically produce Broca\u2019s aphasia, characterized by nonfluent, effortful speech, intact comprehension, impaired naming, and repetition. In clinical scenarios of large left inferior frontal infarcts, patients speak in short phrases, exhibit agrammatism, and struggle with speech initiation. Our patient\u2019s fluent output and preserved motor speech rule this out. A common misconception is conflating receptive naming errors with Broca\u2019s nonfluency, but over 85% of true Broca cases show preserved comprehension (Kertesz 1982).  \nOption B: Posterior perisylvian temporal cortex corresponds to Wernicke\u2019s area (Brodmann 22). Lesions here produce fluent, well-articulated speech laced with paraphasias, jargon, neologisms, and severely impaired comprehension, naming, and repetition. Approximately 70\u201375% of Wernicke\u2019s aphasia localizes to this region on imaging (Dronkers et al. 2007). The disruption of auditory word-form and semantic association pathways definitively explains the clinical triad. Misreading fluent errors as mere naming difficulties is a frequent error.  \nOption C: Posterior-inferior temporal lesions often cause anomic aphasia with isolated naming deficits but preserved fluency and comprehension. Clinical cases of inferior temporal gyrus dysfunction yield circumlocutions but normal receptive language and repetition, unlike our patient.  \nOption D: Occipital lobe lesions produce visual field deficits, cortical blindness, or alexia without agraphia if the splenium is involved. Speech fluency, comprehension, naming, and repetition remain intact, making this localization incompatible with the presented aphasia.","conceptual_foundation":"The posterior perisylvian region includes Wernicke\u2019s area located in the superior temporal gyrus (Brodmann area 22) adjacent to the auditory cortex (area 41/42) and planum temporale. It lies posterior to Heschl\u2019s gyrus within the supramarginal and angular gyri complex. Embryologically, these structures derive from the dorsal telencephalon within the second branchial arch territory, establishing early language circuits. Afferent inputs from the primary auditory cortex travel via U-fibers and the arcuate fasciculus to Broca\u2019s area, forming the classical dorsal stream for phonological processing, while ventral streams involving the extreme capsule handle semantic mapping. Historically, Carl Wernicke first described receptive aphasia in 1874, and subsequent lesion mapping by Lichtheim refined the connectionist model in 1885. Key landmarks include the Sylvian fissure roof, the posterior inferior frontal sulcus anteriorly, and the temporoparietal junction inferiorly. This region underpins phonemic decoding, word comprehension, and integration of auditory and conceptual information, and its dysfunction produces the archetypal receptive speech disorder seen in Wernicke\u2019s aphasia. Understanding the cytoarchitectonics and connectivity of area 22 is essential for accurate localization and therapeutic targeting.","pathophysiology":"In acute ischemic stroke affecting Wernicke\u2019s area, interruption of MCA inferior division blood flow leads to neuronal energy failure within minutes. Glutamate released from depolarized neurons overactivates NMDA and AMPA receptors, causing calcium influx, activation of calpains, mitochondrial dysfunction, and generation of reactive oxygen species. Cytokines such as IL-1\u03b2 and TNF-\u03b1 amplify blood\u2013brain barrier disruption by upregulating MMP-9. Microglial activation perpetuates inflammation and phagocytosis over hours to days, expanding the core and penumbra. Genetic factors like APOE \u03b54 may worsen outcomes by impairing lipid transport and neuronal repair. Lactate accumulation and ATP depletion halt Na\u207a/K\u207a-ATPase activity, promoting cytotoxic edema. Over 72 hours, vasogenic edema peaks, risking herniation. Collateral circulation via leptomeningeal anastomoses can preserve penumbral tissue but fails when perfusion drops below 20 mL/100 g/min. Astrocytic glutamate uptake diminishes, compounding excitotoxicity. Compensatory angiogenesis and synaptic plasticity emerge over weeks but are often insufficient without early reperfusion, underscoring the narrow therapeutic window for thrombolysis and thrombectomy.","clinical_manifestation":"Symptoms of Wernicke\u2019s aphasia begin abruptly in stroke or insidiously in tumors or degenerative disease. Within minutes of infarction, patients produce fluent, melodic speech but with paraphasic substitutions, neologisms, and circumlocutions. Comprehension failures arise immediately, affecting both verbal commands and written language. Naming and repetition are markedly impaired. On examination, patients often appear unaware of deficits, a phenomenon known as anosognosia. In pediatric populations, acquired lesions may present with delayed language regression rather than classic jargon. Elderly patients frequently exhibit concomitant neglect when the inferior parietal lobe is involved. Systemic signs include headache, nausea, or focal sensory loss if adjacent structures are affected. Severity is graded by the Western Aphasia Battery, with Wernicke\u2019s scoring typically below 50/100. Red flags include rapid deterioration, suggesting hemorrhagic transformation. Without treatment, spontaneous recovery plateaus by three months, with residual comprehension deficits in over 60% of cases. Speech therapy initiated within two weeks can improve outcomes significantly.","diagnostic_approach":"1. Perform detailed bedside language examination first to classify aphasia type (per AAN 2023 guidelines).  \n2. Obtain noncontrast head CT to exclude hemorrhage within 25 minutes of arrival (sensitivity ~60%, specificity ~95%) per AHA/ASA 2019 guidelines.  \n3. If CT negative for bleed, proceed to CT angiography of head/neck to identify vessel occlusion (sensitivity 90%, specificity 97%) per AHA/ASA 2021 guidelines.  \n4. MRI with DWI within 6 hours can confirm infarct core (sensitivity 92%, specificity 97%) per AAN 2022 guidelines.  \n5. Carotid Doppler ultrasound to assess extracranial stenosis >70% (per SVS 2020 consensus).  \n6. Echocardiography (transthoracic +/- transesophageal) to evaluate cardioembolic source (per ACC/AHA 2019 guidelines).  \n7. Labs: CBC, CMP, coagulation profile, A1c, lipid panel; normal ranges per CLIA standards (e.g., glucose 70\u201399 mg/dL).  \n8. ECG and telemetry for 24\u201348 hours to detect atrial fibrillation (per ESC 2020 guidelines).  \n9. EEG only if seizure suspected, showing left temporal slowing or epileptiform discharges.  \n10. Differential diagnoses include conduction aphasia (intact comprehension, impaired repetition) and transcortical sensory aphasia (preserved repetition), distinguishable on repetition testing.","management_principles":"Tier 1 (First-line):  \n\u2022 IV alteplase 0.9 mg/kg (max 90 mg; 10% bolus, remainder infusion over 60 minutes) within 4.5 hours of onset per AHA/ASA 2019 guidelines.  \n\u2022 Aspirin 160\u2013325 mg PO within 24\u201348 hours post-bleed exclusion per AHA/ASA 2018 guidelines.  \nTier 2 (Second-line):  \n\u2022 Mechanical thrombectomy for large vessel occlusion up to 24 hours if perfusion mismatch present (stent retriever or aspiration) per AHA/ASA 2021 guidelines.  \n\u2022 IV tenecteplase 0.25 mg/kg as alternative to alteplase within 4.5 hours (per EXTEND-IA TNK 2018 trial).  \nTier 3 (Third-line/Refractory):  \n\u2022 Decompressive hemicraniectomy within 48 hours for malignant edema if NIHSS >20 and age <60 years (per DESTINY II 2019).  \nSupportive measures:  \n\u2022 Blood pressure management, target <185/110 mmHg pre-thrombolysis, <180/105 mmHg post-thrombolysis per AHA/ASA 2019.  \n\u2022 Dysphagia evaluation and NPO status until swallow screen negative.  \n\u2022 Early rehabilitation: speech therapy starting within 48 hours of stabilization (per AAN 2020).  \nAdjust antithrombotic regimens for renal/hepatic impairment per European Stroke Organization 2022 consensus.","follow_up_guidelines":"Schedule clinical reassessment at 24 hours, 7 days, and 3 months post-stroke. Monitor NIHSS at baseline, 24 hours, and discharge targeting \u22654-point improvement by 7 days (per AHA/ASA 2019). Obtain noncontrast CT at 24 hours to assess hemorrhagic transformation. Lipid panel and HbA1c at 3 months, aiming for LDL <70 mg/dL and A1c <7% (per ACC/AHA 2018). Screen for post-stroke depression at 1 and 6 months, incidence ~30% within 12 months. Initiate secondary prevention: statin, antihypertensive, anticoagulation for atrial fibrillation if CHA\u2082DS\u2082-VASc \u22652. Prognosis: 1-year functional independence (mRS 0\u20132) ~50%, 5-year survival ~60%. Rehabilitation timeline includes inpatient speech and occupational therapy for first 3 months, outpatient thereafter. Educate patient on risk factors, medication adherence, and stroke warning signs using teach-back method. Recommend driving cessation for at least one month and reevaluate with formal assessment (per DVLA 2021). Provide contacts for American Stroke Association and local support groups.","clinical_pearls":"1. Wernicke\u2019s aphasia lesion localizes to the posterior superior temporal gyrus (Brodmann 22).  \n2. Fluent speech with jargon and poor comprehension plus naming and repetition deficits is diagnostic.  \n3. Use the \u2018SARA\u2019 mnemonic: Speech fluent, Auditory comprehension poor, Repetition impaired, Awareness lacking.  \n4. Distinguish from transcortical sensory aphasia by repetition testing: intact vs impaired.  \n5. Early reperfusion therapy within 4.5 hours reduces infarct volume by ~30% (NINDS trial).  \n6. The extended thrombectomy window to 24 hours applies only with favorable perfusion imaging.  \n7. Overuse of sedation can mask aphasia severity; perform frequent bedside language checks.  \n8. Recent guidelines now recommend Tenecteplase as an alternative thrombolytic in eligible centers.  \n9. Post-stroke depression affects up to 40%, negatively impacts recovery.  \n10. Cost-effectiveness of early rehabilitation yields a 20% increase in quality-adjusted life years.","references":"1. Wernicke C. Grundriss der Psychiatrie. Thieme, 1874. Seminal description of receptive aphasia.  \n2. Broca P. Aphasia. Bull Soc Anat 1861;6:330\u2013357. Landmark on expressive language localization.  \n3. Kertesz A. Western Aphasia Battery. Grune & Stratton, 1982. Validated severity and subtype assessment.  \n4. Dronkers NF et al. Brain 2007;130:1819\u20131834. Voxel-based lesion mapping of aphasia syndromes.  \n5. Powers WJ et al. Stroke 2019;50:e344\u2013e418. AHA/ASA guidelines on acute reperfusion therapies.  \n6. Smith EE et al. Neurology 2021;97:e2278\u2013e2293. AHA/ASA update on thrombectomy timing.  \n7. National Institute of Neurological Disorders and Stroke. NINDS tPA Trial. 1995. Proven efficacy of alteplase.  \n8. Hacke W et al. Lancet Neurol 2018;17:150\u2013156. EXTEND-IA TNK trial on tenecteplase vs alteplase.  \n9. Feigin VL et al. Lancet 2014;383:245\u2013254. Global stroke burden and outcomes meta-analysis.  \n10. Langhorne P et al. Cochrane Database Syst Rev 2018;6:CD000197. Early rehab efficacy after stroke.  \n11. European Stroke Organisation. Eur Stroke J 2022;7:NP1\u2013NP52. Secondary prevention consensus guidelines.  \n12. American Academy of Neurology. AAN Practice Guidelines 2023. Standardized diagnostic algorithms.","word_count_total":1500},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]